Plain-English translation of NCT06480383 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing a new medication called ITI-1284 to see if it can help reduce anxiety in people with generalized anxiety disorder who haven't improved enough with standard treatments. You would take this medication alongside your current anxiety medication for 6 weeks while researchers measure how much it helps and whether it's safe. The study compares two different doses of the medication against a placebo (an inactive pill) to find the most effective approach.
Many people with generalized anxiety disorder don't get enough relief from the standard medications available today, even when taking them at the right dose for long enough. This trial exists to find out whether this new treatment option could help people who are still struggling with anxiety symptoms despite being on approved anxiety medications.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic three times over about 10 weeks. First, there's a screening visit (up to 3 weeks) where doctors confirm you qualify. Then you enter the 6-week main study period, where you'll randomly receive either one of two doses of the new medication or a placebo pill to take daily alongside your regular anxiety medication—you won't know which one you're getting. Finally, you'll have a follow-up safety visit 1 week after the study ends to make sure you're doing well.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
United States